Podcasts about steroidal

Live from ESC Congress 2024! In this edition of Don't Miss a Beat, Stephen Greene, MD, an advanced heart failure specialist at Duke University School of Medicine, discusses the prospect of finerenone in treatment algorithms for heart failure with Muthiah Vaduganathan, MD, MPH, codirector of the Center for Cardiometabolic Implementation Science of Brigham and Women's Hospital, based on data from the meeting, including FINEARTS-HF, FINE-HEART, and an analysis on MRA use in heart failure. Chapters 00:00 - Welcome and Introduction 01:18 - FINEARTS-HF Study Design and Patient Population 03:04 - Inclusion of Hospitalized Patients 04:43 - Primary and Secondary Endpoints 05:56 - Challenges in Achieving Statistical Significance 07:39 - Health Status Improvement and Additional Analyses 10:01 - Combination Therapy and Future Trials 12:20 - Hyperkalemia and Steroidal vs. Non-Steroidal MRAs 15:30 - Conclusion and Acknowledgments

Naturopath Ben Lee shares his clinical insights into the challenges associated with topical steroid withdrawal. With skin conditions so prevalent in our society, the prescribing of topical steroids is on the rise. Ben's integrated approach to firstly identifying the condition, and then treating from the root cause addresses the mechanisms of action, the signs and symptoms to look out for, and how we as healthcare professionals can best support others to reduce symptoms and optimise skin integrity. Find today's transcript and show notes here: https://www.fxmedicine.com.au/podcast/naturopathic-support-topical-steroidal-withdrawal-emma-sutherland-and-ben-lee Sign up for our monthly newsletter for the latest exclusive clinical tools, articles, and infographics: https://pages.blackmores.com.au/FXM-signup.html ***DISCLAIMER: The information provided on fx Medicine is for educational and informational purposes only. The information provided is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you learn here raises questions or concerns regarding your health.***

Humans have had an insatiable appetite for inhibiting production of prostaglandins for centuries! This series delves into the history of aspirin and NSAIDs, looking at the understanding of the prostaglandin pathway. ·       Intro 0:12 ·       In this episode 0:23 ·       What are NSAIDs? 0:53 ·       Prostaglandins 5:50 ·       What are prostaglandins? 7:19 ·       Where do prostaglandins come from? 8:45 ·       So, what do we do with prostaglandins? 13:15 ·       How did they figure out prostaglandins? 13:55 ·       Naming the prostaglandin 21:25 ·       Phospholipids 24:46 ·       Arachidonic acid 25:28 ·       Arachidonic acid into prostaglandins: how do you prove it? 26:32 ·       How does arachidonic acid turn into prostaglandins? 27:27 ·       Cyclo-oxygenase 28:36 ·       mRNA and COX-2 32:50 ·       On the next episode 35:55 ·       Summary 36:38 ·       Thanks for listening 37:49 Disclosures: Brown reports no relevant financial disclosures. We'd love to hear from you! Send your comments/questions to Dr. Brown at rheuminationspodcast@healio.com. Follow us on Twitter @HRheuminations @AdamJBrownMD @HealioRheum. References: Botting RM. Pharmacol Rep. 2010;doi:10.1016/s1734-1140(10)70308-x. Flower RJ. Br J Pharmacol. 2006;doi:10.1038/sj.bjp.0706506. Flower RJ. Br J Pharmacol. 2019;doi:10.1111/bph.14588. Kurzrok R, et al. Exp Biol Med. 1930;doi:10.3181/00379727-28-5265. https://www.nobelprize.org/prizes/medicine/1970/euler/biographical/. von Euler US. J Physiol. 1936;doi:10.1113/jphysiol.1936.sp003433.

NSAIDs are widely recommended and used to alleviate pain. Their name may – anti-inflammatory – may seem to indicate that they are helping you to reduce the inflammation that is the ‘engine' behind your Endometriosis. But will they? And are their possible concerns about taking them? I cover these questions in this podcast episode. If you'd like to have a chat about how you can move away from NSAIDs and use nutrition to manage your symptoms, book a complimentary Endometriosis SOS Call now: https://eatwelllivewell.com.au/endometriosis-sos-call/

While effective for acute pain control, recent pre-clinical evidence has raised concerns regarding an association between NSAIDs and chronic pain and potential opioid use. The objective of this paper was to explore the association between peri-operative use of prescription NSAIDs and the need for continued opioid prescriptions lasting 90–180 days in previously opioid-naïve patients undergoing total knee arthroplasty. Join Prof Ed Mariano and the authors to find out what the key messages are for clinicians.

Professor Riccardo Asero joins Professor Marcus Maurer to offer advice on the use of non-steroidal anti-inflammatory drugs (NSAID) in people with chronic spontaneous urticaria (CSU). The experts discuss risk assessment and strategies to avoid respiratory and cutaneous hypersensitivity reactions in people who require these common medications to manage comorbidities. Do you have suggestions for future episodes? Please provide feedback and offer your suggestions for future topics and expert selection here. Utilise the following external links to access additional resources relating to the topics discussed in this episode: Nonsteroidal anti-inflammatory drugs hypersensitivity in chronic spontaneous urticaria in the light of its pathogenesis and Progress in understanding hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Access additional resources by signing up to Medthority and to be notified for future ‘All Things Urticaria' podcast episodes! For more information about the UCARE/ACARE network and its activities, please visit: UCARE Website, UCARE LevelUp Program, ACARE Website, UCARE 4U Website, UDAY Website, CRUSE Control App and CURE Registry.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:https://www.mycme.com/courses/the-role-of-non-steroidal-mras-in-chronic-kidney-disease-8866Featuring faculty Robert D. Toto, MD, moderated by Gregg Sherman, MD.SummaryChronic kidney disease (CKD) is estimated to affect 20%–40% of patients with diabetes mellitus. In renal disease, increased production of aldosterone and other mediators leads to overactivation of the mineralocorticoid receptor (MR). In turn, overactivation of the MR can drive progression of renal disease. Through these mechanisms, increased aldosterone production and MR overactivation contribute to adverse renal, cardiac, and vascular effects. Traditional steroidal MR antagonists (MRAs) are beneficial but are associated with hyperkalemia. However, a newer nonsteroidal MRA is available that targets MR overactivation without the risk of hyperkalemia.In this second of two podcast episodes, Dr. Robert Toto and Dr. Gregg Sherman discuss identifying appropriate candidates for nonsteroidal MRAs, as well as incorporating these therapies into the management of CKD of T2D.This podcast was recorded and is being used with permission of the presenters.Learning ObjectiveUpon completion of this activity, learners should be able to:Identify patients with CKD and T2D who are appropriate candidates for non-steroidal MRAs to manage residual riskThis activity is accredited for CME/CE Credit.The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0.25 hours of pharmacology).Summary of Individual DisclosuresRobert Toto has disclosed the following financial relationships:Consultant: Amgen (Anemia in CKD), AstraZeneca (CKD), Akebia (Anemia in CKD), Bayer (CKD), Boehringer Ingelheim (CKD), Medscape (CKD anemia and hyperkalemia), Novartis (CKD), Novo Nordisk (Diabetic Kidney Disease), Otsuka (Anemia in CKD), Vifor (CKD), CinCor (CKD)Advisor – Unicycive (hyperphosphatemia in CKD)Angela Golden has disclosed the following financial relationships:Consultant: SetPoint (Obesity), WW (Obesity)Advisor: Currax (Obesity), Genesis (Obesity), Lilly (Obesity), Novo Nordisk (Obesity), (Obesity), Acela (Hypothyroidism)Speaker: Currax, Novo Nordisk (Obesity)Receipt of Royalty: Amazon (fiction books), Springer (obesity book)Faculty, planners, guest patient(s) (if applicable), and moderators for this educational activity not listed in the Summary of Individual Disclosures above have no relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.Disclosure of Commercial SupportThis activity has been supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.Please visit http://naceonline.com to engage in more live and on demand CME/CE content.

Please visit answersincme.com/PGS860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses integrating non-steroidal mineralocorticoid receptor antagonists (MRAs) in the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.

Please visit answersincme.com/TVT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in endocrinology discusses how to optimize the use of novel non-steroidal mineralocorticoid receptor antagonists (MRAs) for patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.

Please visit answersincme.com/PRH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in nephrology discusses the guideline-recommended approach to incorporating non-steroidal mineralocorticoid receptor antagonists (MRAs) into the treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). Upon completion of this activity, participants should be better able to: Describe the role of non-steroidal MRAs in the treatment of patients with CKD and T2D; Evaluate the clinical impact of the latest safety and efficacy data for novel non-steroidal MRAs in patients with CKD and T2D; Review the latest guideline updates informing the use of novel non-steroidal MRAs in patients with CKD and T2D; Identify patients with CKD and T2D who might benefit from treatment with novel non-steroidal MRAs; and Formulate treatment plans for patients with CKD and T2D that incorporate the latest evidence and guideline updates for non-steroidal MRAs.

You'll have to forgive my self-indulgence in this conversation, because I've gone deep with Joshi Herrmann—not a celebrity name or a celebrated author, I hope he won't be offended by me saying—about a bunch of things that scratch my particular interests in media: local news, New York media-startup scandals circa 2016, subscriptions versus ads, venture capital, and canceled Netflix comedians. Joshi is the founder of a fledgling media empire anchored by The Mill, a local news publication covering the city of Manchester, England, that he launched in 2020. The Mill, which is based entirely on Substack and funded by subscribers, just reached profitability—a rare success story in a space (local news) that hasn't exactly been booming in recent years. Encouraged by The Mill's progress, Joshi has since launched similar publications in Sheffield and Liverpool based on doing high-quality, low-volume longform reporting on issues that matter to cities that are poorly served by the existing media structure. Joshi was a reporter for the Evening Standard in London for four years before, in 2015, he moved to New York for a dream job as the editor in chief for a startup that published The Tab, a news site written by university students and young people about the cultural issues of the time. The Tab quickly gave rise to a spinoff publication called Babe.net, which shot to notoriety after publishing a story that detailed a young woman's bad night with Aziz Ansari, which led to the comedian's “cancellation.” The story came at the height of #MeToo, causing a fiery debate between people who felt it was an important reckoning for behavior that happens often but is under-discussed and those who felt it muddied the lines between truly abusive behavior and something closer to a bad date. Joshi watched it all unfold from an uncomfortable position: he was the editor on that story…Joshi's recommended reads:The Bluestocking, PassTheAux, and Vittles.Show notes* Subscribe to The Mill in Manchester on Substack, as well as its sister sites, Sheffield Tribune in Sheffield, and The Post in Liverpool* The Tab and Babe.net* Aziz Ansari story on Babe.net and Ansari's response* NYT commentary on the Babe.net piece* The Cut on Babe.net* [1:46] Breaking even in local news* [1:55] Feeling like a fraud* [4:48] Getting into local journalism* [8:07] On losing a parent* [12:00] Pursuing an unpromising venture* [13:55] Redefining the problem of local news  * [18:56] Joining The Tab in New York* [22:41] Steroidal audience growth vs. community* [25:25] The “bullshit” of new media's gold-rush era* [26:37] How Babe.net started* [28:28] How Babe broke the Aziz Ansari story* [30:17] How the Ansari story relates to Me Too* [38:06] Lessons from being on the other side of the story* [39:51] Reflections on that time* [41:40] Adapting a new approach to longform* [44:48] Shutting down The Tab and Babe.net* [46:06] Life lessons for The Mill* [47:55] Launching two sister sites in the U.K.* [48:38] The public hunger for great local journalismThe Active Voice is a podcast hosted by Hamish McKenzie, featuring weekly conversations with writers about how the internet is affecting the way they live and write. It is produced by Hanne Winarsky, with audio engineering by Seven Morris, content production by Hannah Ray, and production support from Bailey Richardson. All artwork is by Joro Chen, and music is by Phelps & Munro. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit read.substack.com

Commentary by Dr. Anita Deswal

This episode features Dr Andrew Page (Academic Unit of Palliative Care, Leeds Institute of Health Sciences, University of Leeds, Leeds, UK). Cancer pain is common, extremely debilitating, and undertreated worldwide. We do not know if non-steroidal anti-inflammatory drugs (aka NSAIDs or “anti-inflammatories”) are effective in managing cancer pain of any type. To further scientific understanding, UK palliative care doctors advocate a pragmatic trial to determine the role, if any, of NSAIDs as opioid adjuncts for treating cancer-induced bone pain. Numbers treated for cancer-induced bone pain at a single regional radiotherapy centre (478 per year) support the feasibility of trial recruitment. Considering eGFR and contraindicating co-morbidities, two-thirds could be suitable for NSAID prescription if proven efficacious. Suitability for NSAID prescription reduces with age, with the proportion unsuitable increasing in those over 65 years old. Recruitment to a future trial of NSAIDs in the management of cancer-induced bone pain appears feasible, particularly if multiple recruitment centres are used. Demonstrating feasibility allows the planning of a definitive clinical trial to determine the efficacy of NSAIDs in this patient group. Without a definitive clinical trial, the question remains: are effective analgesics being underutilised in cancer pain management, or are ineffective medications increasing the risk of side effects in an already co-morbid cancer population? Full paper available from:     https://journals.sagepub.com/doi/full/10.1177/02692163221122263 If you would like to record a podcast about your published (or accepted) Palliative Medicine paper, please contact Dr Amara Nwosu:  a.nwosu@lancaster.ac.uk

Guest: Mikhail Kosiborod, MD Patients with diabetes-related chronic kidney disease (CKD) are at high risk for a number of adverse events over a relatively short period of time. So what do we have in terms of efficacious therapies that can help make a positive impact in that regard? Here to share what we need to know about non-steroidal mineralocorticoid receptor antagonists (MRAs) for the treatment of diabetes-related CKD is Dr. Mikhail Kosiborod, Director of Cardiometabolic Research and Co-Director of the Haverty Cardiometabolic Center of Excellence at Saint Luke's Mid America Heart Institute.

In this special podcast series, CMHC co-chair George Bakris, MD, Professor of Medicine at University of Chicago is joined by Rajiv Agarwal, MD, Professor of Medicine at Indiana University School of Medicine, and Katherine Tuttle, MD, Professor of Medicine at University of Washington, to discuss important considerations and pearls about the screening, diagnosis, and treatment of CKD in patients with type 2 diabetes, as well as advances and updates.    Recorded July 25, 2022

In this episode, Ted and Josh talk about their favorite steroidal athletes. That's basically it. Follow us on the socials:Facebook: https://www.facebook.com/Kluck-108506628317783Twitter: https://twitter.com/kluckcastInstagram: https://www.instagram.com/kluckcast/

Welcome back for episode 141 of The Bodybuilding Dietitians Podcast! On this week's episode Tyarra and Jack answer and discuss various topics including: - Should you start reversing if you've been dieting for six months? - Can you have abs at any level of body fat? - Exercise, inflammation and fluid retention explained - Can NSAIDS reduce muscle hypertrophy? - Tips For Sleep Hygiene - TBD TEES ARE NOW AVAILABLE Link for TBD Tees: https://www.thebodybuildingdietitians.com/tbdapparel/qhk1uy9fz085ldg2jbeofrobnre9u6 Thank you again for tuning into the podcast and we hope you enjoy! We would greatly appreciate if you would please subscribe to the channel, give us a rating, leave us a review and tell your friends about the podcast! The more people we can reach out to and help the better! Stay tuned for more podcasts released on a weekly basis! Business Website: www.thebodybuildingdietitians.com Tyarra's Instagram: www.instagram.com/tyarranelson/?hl=en Jack's Instagram: www.instagram.com/jack.radfordsmith/?hl=en The Bodybuilding Dietitians Instagram: www.instagram.com/thebodybuildingdietitians/?hl=en YouTube: www.youtube.com/channel/UC9Why7CvHSXNMG8Aws6dnww 10% Off Marmadukes Peanut Butter Powder (discount code TBD10): www.marmadukes.com.au/discount/TBD10 VPA 10% off codes used at checkout: www.vpa.com.au/ TYARRA JACK

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 1 - Recognizing and Reducing Hyperkalemia Risk in CKD PatientsFeaturing George Bakris, MD as faculty, moderated by Robert D. Toto, MD. SummaryIn this 3-part educational podcast series moderated by Dr. Robert D. Toto, faculty discuss the management of chronic kidney disease using a non-steroidal MRA and what you really need to know now. In part 1, Dr. George Bakris and Dr. Robert D. Toto discuss the clinical risks of hyperkalemia in chronic kidney disease and ways to reduce these risks.Chronic kidney disease (CKD) is associated with increased cardiovascular risk, and mortality in CKD patients is often due to cardiovascular disease (CVD). Inflammation, fibrosis, and the mineralocorticoid receptor (MR) play important roles in CKD progression and CVD risk, while MR antagonists (MRAs) reduce CVD risk and CKD progression. Older steroidal MRAs have several limitations, including causing hyperkalemia, which is a potentially serious electrolyte abnormality that is already more common among CKD patients. This podcast series will provide clinicians with additional information on available MRAs and how to use them in the care of patients with CKD.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify strategies to reduce the risk of hyperkalemia in patients with CKDThis activity is accredited for CME/CE Credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 1 - Recognizing and Reducing Hyperkalemia Risk in CKD PatientsThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 3 -Managing CKD: The Role of Non-Steroidal MRAsFeaturing Katherine R. Tuttle, MD, FASN, FACP, FNKF as faculty, moderated by Robert D. Toto, MD.SummaryIn this 3-part educational podcast series moderated by Dr. Robert D. Toto, faculty discuss the management of chronic kidney disease using a non-steroidal MRA and what you really need to know now. In part 3, Dr. Katherine Tuttle and Dr. Robert D. Toto discuss exciting new developments in the management of patients with diabetic kidney disease.Chronic kidney disease (CKD) is associated with increased cardiovascular risk, and mortality in CKD patients is often due to cardiovascular disease (CVD). Inflammation, fibrosis, and the mineralocorticoid receptor (MR) play important roles in CKD progression and CVD risk, while MR antagonists (MRAs) reduce CVD risk and CKD progression. Older steroidal MRAs have several limitations, including causing hyperkalemia, which is a potentially serious electrolyte abnormality that is already more common among CKD patients. This podcast series will provide clinicians with additional information on available MRAs and how to use them in the care of patients with CKD.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Identify patients who are appropriate candidates for non-steroidal MRAs in the management of CKDThis activity is accredited for CME/CE credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 3 -Managing CKD: The Role of Non-Steroidal MRAsThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit: Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 2 -CKD and Cardiovascular Risk - The Evolving ConnectionFeaturing George Bakris, MD as faculty, moderated by Robert D. Toto, MD.SummaryIn this 3-part educational podcast series moderated by Dr. Robert D. Toto, faculty discuss the management of chronic kidney disease using a non-steroidal MRA and what you really need to know now. In part 2, Dr. George Bakris and Dr. Robert D. Toto discuss the roles of inflammation, fibrosis, and the mineralocorticoid receptor in the progression of chronic kidney disease.Chronic kidney disease (CKD) is associated with increased cardiovascular risk, and mortality in CKD patients is often due to cardiovascular disease (CVD). Inflammation, fibrosis, and the mineralocorticoid receptor (MR) play important roles in CKD progression and CVD risk, while MR antagonists (MRAs) reduce CVD risk and CKD progression. Older steroidal MRAs have several limitations, including causing hyperkalemia, which is a potentially serious electrolyte abnormality that is already more common among CKD patients. This podcast series will provide clinicians with additional information on available MRAs and how to use them in the care of patients with CKD.This podcast was recorded and is being used with the permission of the presenters.Learning ObjectivesUpon completion of this activity, learners should be able to:Recognize how inflammation, fibrosis, and the MR play a role in the progression of CKD, including their impact on cardiovascular riskThis activity is accredited for CME/CE credit.For more information regarding this CME/CE activity and to complete the CME/CE requirements and claim credit for this activity, visit:Considering a Non-Steroidal MRA for CKD...Here's What You Need to Know! Part 2 -CKD and Cardiovascular Risk - The Evolving ConnectionThe National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.The National Association for Continuing Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.National Association for Continuing Education is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 121222. This activity is approved for 0.25 contact hours (which includes 0 hours of pharmacology).This activity is supported by an educational grant from Bayer HealthCare Pharmaceuticals Inc.

Dr. Brian Cole and Steve Kashul discuss the positive and negative impacts of non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen and naproxen.

Hello everyone, welcome to the CattleCalPodcast! This is the first podcast of the new “Feedlot Research” series. For the next 6 months, we will be discussing research publications related to hormone implants in feedlot cattle. In this episode, we talked about the article entitled: “Effects of steroidal implants on feedlot performance, carcass characteristics, and serum and meat estradiol-17β concentrations of Holstein steers”, written by Carvalho et al. (2020). If you want to receive a pdf copy of the article, please send an email to cattlecalucd@gmail.com with the title “Feedlot Research Request”, and we will send it to you. Enjoy the call. Follow CattleCal on Instagram: https://www.instagram.com/cattlecal/ Subscribe to our monthly newsletter: http://ceimperial.ucanr.edu/news_359/CattleCal_483/ Send an email to cattlecalucd@gmail.com with questions and feedback. Thank you very much! And remember: "It is always a great time for a CattleCal".

Soft tissue injuries are common and one of the Cochrane Reviews of their treatment was updated in August 2020 to assess the effects of different types of pain killer. Here's Peter Jones from Auckland City Hospital in New Zealand to outline the latest findings.

Soft tissue injuries are common and one of the Cochrane Reviews of their treatment was updated in August 2020 to assess the effects of different types of pain killer. Here's Peter Jones from Auckland City Hospital in New Zealand to outline the latest findings.

Credits: 0.25 AMA PRA Category 1 Credit™ Claim CME/CE credit: https://www.pri-med.com/online-education/podcast/rems-podcast-4-nsaids-8-20  Overview: Nonsteroidal anti-inflammatory drugs (NSAIDs) are used for pain management in a variety of settings and for a variety of conditions. This podcast summarizes the evidence for efficacy as well as for toxicities associated with this drug class and outlines current guideline recommendations. This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://ce.opioidanalgesicrems.com/RpcCEUI/rems/pdf/resources/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration (FDA). Guest: Oscar A. De Leon-Casasola, MD

Commentary by Dr. Valentin Fuster

What are NSAIDs and how do they work? In this episode we discuss aspirin, ibuprofen, naproxen, diclofenac, celecoxib, and paracetamol.

Steroid eye drops do come with side effects, meaning that we must ensure that they're used carefully and with caution. Of course, there are many cases where the benefits in the use of steroids far outweigh the risks of using them, and this risk-benefit ratio is something optometrists and ophthalmologists must always keep in mind.   

Q&A from Alina's talk at the Veterinary Evidence Today conference, Edinburgh November 1st, 2016. Read more, view the slides and listen to the full talk here.

Acute puerperal metritis (APM) is a potentially life threatening, painful disease and is often treated with third-generation cephalosporins. Due to increasing antibiotic resistance, Alina discusses the need to evaluate alternative therapies to antibiotics. Read more, view the slides and listen to the Q&A here.     AP - Efficacy of Nonsteroidal Antiinflammatory Drugs for the Treatment of Acute Puerperal Metritis in Dairy Cow  Veterinary Evidence TodayEdinburgh, 1-3 November 2016

What do we do when diet and exercise don't work? Do hormones and our nervous system hold the key? Today, I'm excited and honored to have Reed Davis on Wellness Force Radio to unlock the answers and uncover the hidden causes of weight gain. Support Wellness Force Radio:  RATE & REVIEW in iTunes |  SUBSCRIBE in iTunes | Reed is the Founder of the Functional Diagnostic Nutrition® (FDN) Certification Course.  He is known as one of the most successful and experienced clinicians in the world, having provided functional lab assessments to over 10,000 clients for hormone, adrenal, digestive, immune and detoxification issues as well as infections, infestations, food sensitivities and chronic stress-related problems. Reed served as a Health Director and Case Manager for over 15 years and now teaches a course in functional medicine with over 2,000 trainees in 50 countries. He is also a Clinical Advisor at BioHealth Laboratory where he helps doctors interpret lab test results and develop natural protocols to restore function instead of just treating the symptoms. While serving for many years as the CNT and Case Manager, Reed Davis made his own observations about who got better and who did not. The patients who improved the most were the ones working as close to the underlying cause as possible, and not simply treating the symptoms. Wanting to help as many people as possible, Reed employed functional lab testing as it applies to nutrition and other natural protocols with thousands of patients. Educating others became a passion and provided a mission that Reed carries out to this day. While systematizing the work, Reed came to the realization that he had discovered an emerging field. He named this growing body of work Functional Diagnostic Nutrition® and founded the certification course. Special Notes: Learn More About becoming your own health detective as a Certified FDN Practitioner To Get Your Free D.R.E.S.S For Health Success Manual, Text: "Josh" to 802 467 0057 Listen as Reed Uncovers: How to find the root cause(s) of what is holding back your optimal wellness The mindset and accountability needed to create lasting health  Action steps for listeners in self-quantification and lab testing Links From Today's Show: FDN Training Course Reed Davis, Biography What is Metabolic Chaos? Show Notes & Blog Post Today's Show Topics: What is FDN? Who is FDN for? What impact is FDN making in health and wellness? How does FDN support homeostasis and finding the root cause The broken health model of today What FDN coaches do to impact their clients ------------------------------------------------------------------------------------------------------------------ Steroidal hormones and adrenal function Symptoms that lead people to look for new answers Adrenal Fatigue, review and supporting healing Oxidative Stress, the hidden causes Pathogens, identifying and healing Mucosal Barrier, function and signs of support Blocking factors and toxic load ------------------------------------------------------------------------------------------------------------------ D.R.E.S.S for success Coaching to win, how to become a health detective The mindset for sustaining positive health change  Accountability Keystone habits to sustain health How the right coach uses quantification to create sustainable change   Are You Interested In Changing Old Habits With New Technology? Download your free Digital Health Transformation Guide at wellnessforce.com/radio Don't miss next week's show! Subscribe to the show and stay updated If this show resonated with you, please us an honest rating and review The more reviews and ratings we receive, the more people we can reach with this amazing message!    You May Also Like These Episodes: Healthy, Happy & Harder To Kill w/ Steph Gaudreau of Stupid Easy Paleo Beyond Meditation: How To Get A Better Brain With Ariel Garten Living A Healthy Lifestyle In A Modern World With Dan Pardi  How To Get Out of Your Head & Into Your Body With Danny-J Johnson The Hidden Causes of Weight Gain with Reed Davis

"We can't live without bacteria. They help us digest, absorb and metabolise nutrients in our food."  Alexandra Jamieson. Come and take our free cravings quiz to get your cravings profile: http://alexandrajamieson.com

Raised by her single mother, Chitoka Webb grew up in the Preston Taylor housing projects, landed her first job in a grocery store at only 13 years old. When a senior in High School, she was told by school authorities she couldn’t graduate with her class just a week before the ceremony due to being one point short in her chemistry class. Now, in her mid-30s, Webb owns several businesses—that she founded. She began her self employed career at 23. In 1999 Webb left Nashville and moved to Atlanta, where she nurtured numerous relationships with professional athletes and successful business leaders. Working as the only female barber alongside 14 other male barbers. Her highlight moment came during Super Bowl XXXIV when she was invited by her client Anthony Dorsett (Son of football great Tony Dorsett) to attend the event as their barber. After much success and accomplishing set goals she returned to Nashville in pursuit of a dream to own her own barbershop, which she opened in October 2001. She worked three full time jobs for three months to make this dream a reality. Her life and business motto is “Do unto others as you would have them do unto you” pulling herself up by the bootstraps these humble beginnings brought more success. After developing two health care agencies and a new state-of-the-art barbershop Webb developed Chitoka L.Webb Holdings, Inc. which oversees her professional ventures, and the early development stages of a Foundation which supports her community service projects Through her impressive business growth, Webb suffered blindness for six months as a result of Behcet’s disease. High doses of Steroidal eye injections and medications corrected her failed eye sight. The Behcet’s diagnosis led Webb to write her memoir, Something Inside of Me. Join Kelli & Gina as they interview Chitoka Webb on August 31, 2011 at 2:00 p.m. EST

Guest: Mark G. Lebwohl, MD Host: Michael Greenberg, MD Dr. Michael Greenberg interviews Dr. Mark Lebwohl, Professor of Dermatology from the Mount Sinai School of Medicine in New York. Dr. Lebwohl discusses Protopic, Elidel, the myths and realities behind their safety for patients.

Autoregulation is a control mechanism common to several proteins of the steroid/thyroid hormone receptor superfamily. In this work the effect of androgens and antiandrogens on the expression of the human androgen receptor (hAR) in prostate and breast cancer cell lines was studied. Northern blot analysis revealed a decrease in hAR steady state RNA levels in LNCaP cells by 3.3 nht of the synthetic androgen mibolerone. Maximal down-regulation of hAR RNA to 30% of control levels occurred 48 h after hormone addition. T47D breast cancer cells showed a similar effect with mibolerone, while hAR expression in normal skin fibroblasts did not respond to androgen treatment. As shown by nuclease Sl analysis, hAR transcripts initiate at three principal start sites, all of which are equally sensitive to androgen. Steroidal as well as nonsteroidal antiandrogens were capable of partially antagonizing androgen-mediated hAR RNA down-regulation in LNCaP and T47D cells, while not exerting a significant effect when administered alone. While hAR RNA stability was increased by hormone, nuclear run-on analysis revealed a 4-fold reduction of hAR gene transcrip tion 98 h after androgen treatment. Although decreased hAR RNA levels did not coincide with a parallel decrease in AR protein levels, analysis of androgen-inducible reporter constructs demonstrated that prolonged androgen administration to ceils results in a progressively impaired sensitivity of the intracellular androgen response mechanism. These results show that prolonged androgen exposure leads, besides its effect on hAR RNA levels, to functional inactivation of the AR. Thus, in viva, posttranslational control of AR activity appears to be a novel mechanism of negative autoregulation of androgen effects on gene expression.